P63 regulates glutaminase 2 expression

Cell Cycle

Volumn 12, Issue 9, 2013, Pages 1395-1405

  Giacobbe, Arianna ^a   Bongiorno Borbone, Lucilla ^a   Bernassola, Francesca ^a   Terrinoni, Alessandro ^a   Markert, Elke Katrin ^b   Levine, Arnold J ^b   Feng, Zhaohui ^c   Agostini, Massimilano ^d   Zolla, Lello ^e   Agrò, Alessandro Finazzi ^a   Notterman, Daniel A ^f   Melino, Gerry ^a,d   Peschiaroli, Angelo ^g  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b INSTITUTE FOR ADVANCED STUDY   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e UNIVERSITY OF TUSCIA   (Italy)

^f PENNSYLVANIA STATE UNIVERSITY   (United States)

^g CNR   (Italy)

Author keywords

Colon carcinoma; Glutaminolysis; P63; Skin differentiation

Indexed keywords

GLUTAMINASE; GLUTAMINASE 2; LUCIFERASE; MITOCHONDRIAL ENZYME; PROTEIN P53; PROTEIN P63; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL DIFFERENTIATION; CELL LEVEL; CELL METABOLISM; CHROMATIN IMMUNOPRECIPITATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; ENZYME ASSAY; ENZYME BINDING; ENZYME REGULATION; EPIDERMIS CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; KERATINOCYTE; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; TRANSCRIPTION REGULATION; TUMOR CELL LINE; UPREGULATION;

EID: 84877127022     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.24478     Document Type: Article

References (75)

1. Amelio I, Grespi F, Annicchiarico-Petruzzelli M, Melino G. p63 the guardian of human reproduction. Cell Cycle 2012; 11:4545-51; PMID:23165243; http://dx.doi.org/10.4161/cc.22819.
2. Marcel V, Dichtel-Danjoy ML, Sagne C, Hafsi H, Ma D, Ortiz-Cuaran S, et al. Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ 2011; 18:1815-24; PMID:21941372; http://dx.doi.org/10.1038/cdd.2011.120.
3. Levrero M, De Laurenzi V, Costanzo A, Gong J, Melino G, Wang JY. Structure, function and regulation of p63 and p73. Cell Death Differ 1999; 6:1146-53; PMID:10637429; http://dx.doi.org/10.1038/sj.cdd.4400624.
4. Tissir F, Goffinet AM. p73 and p63: Estranged relatives? Cell Cycle 2011; 10:1351; PMID:21460637; http://dx.doi.org/10.4161/cc.10.9.15383.
5. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2:305-16; PMID:9774969; http://dx.doi.org/10.1016/S1097-2765(00)80275-0.
6. Petitjean A, Ruptier C, Tribollet V, Hautefeuille A, Chardon F, Cavard C, et al. Properties of the six isoforms of p63: p53-like regulation in response to genotoxic stress and cross talk with DeltaNp73. Carcinogenesis 2008; 29:273-81; PMID:18048390; http://dx.doi.org/10.1093/carcin/bgm258.
7. Seitz SJ, Schleithoff ES, Koch A, Schuster A, Teufel A, Staib F, et al. Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. Int J Cancer 2010; 126:2049-66; PMID:19711344.
8. Vandenabeele P, Melino G. The flick of a switch: which death program to choose? Cell Death Differ 2012; 19:1093-5; PMID:22684093; http://dx.doi.org/10. 1038/cdd.2012.65.
9. Bellomaria A, Barbato G, Melino G, Paci M, Melino S. Recognition mechanism of p63 by the E3 ligase Itch: novel strategy in the study and inhibition of this interaction. Cell Cycle 2012; 11:3638-48; PMID:22935697; http://dx.doi.org/10.4161/cc.21918.
10. Ghioni P, Bolognese F, Duijf PH, Van Bokhoven H, Mantovani R, Guerrini L. Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol Cell Biol 2002; 22:8659-68; PMID:12446784; http://dx.doi.org/10.1128/MCB.22.24.8659-8668.2002.
11. Helton ES, Zhu J, Chen X. The unique NH2-terminally deleted (DeltaN) residues, the PXXP motif, and the PPXY motif are required for the transcriptional activity of the DeltaN variant of p63. J Biol Chem 2006; 281:2533-42; PMID:16319057; http://dx.doi.org/10.1074/jbc.M507964200.
12. Duijf PH, Vanmolkot KR, Propping P, Friedl W, Krieger E, McKeon F, et al. Gain-of-function mutation in ADULT syndrome reveals the presence of a second transactivation domain in p63. Hum Mol Genet 2002; 11:799-804; PMID:11929852; http://dx.doi.org/10.1093/hmg/11.7.799.
13. Peschiaroli A, Scialpi F, Bernassola F. El Sherbiniel S, Melino G. The E3 ubiquitin ligase WWP1 regulates DeltaNp63-dependent transcription through Lys63 linkages. Biochem Biophys Res Commun 2010; 402:425-30; PMID:20951678; http://dx.doi.org/10.1016/j.bbrc.2010.10.050.
14. Leonard MK, Kommagani R, Payal V, Mayo LD, Shamma HN, Kadakia MP. ΔNp63α regulates keratinocyte proliferation by controlling PTEN expression and localization. Cell Death Differ 2011; 18:1924-33; PMID:21637289; http://dx.doi.org/10.1038/cdd.2011.73.
15. Shalom-Feuerstein R, Lena AM, Zhou H, De La Forest Divonne S, Van Bokhoven H, Candi E, et al. ΔNp63 is an ectodermal gatekeeper of epidermal morphogenesis. Cell Death Differ 2011; 18:887-96; PMID:21127502; http://dx.doi.org/10.1038/cdd.2010.159.
16. Senoo M, Pinto F, Crum CP, McKeon F. p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell 2007; 129:523-36; PMID:17482546; http://dx.doi.org/10.1016/j.cell.2007.02.045.
17. Candi E, Rufini A, Terrinoni A, Giamboi-Miraglia A, Lena AM, Mantovani R, et al. DeltaNp63 regulates thymic development through enhanced expression of FgfR2 and Jag2. Proc Natl Acad Sci USA 2007; 104:11999-2004; PMID:17626181; http://dx.doi.org/10.1073/pnas.0703458104.
18. Rivetti di Val Cervo P, Lena AM, Nicoloso M, Rossi S, Mancini M, Zhou H, et al. p63-microRNA feedback in keratinocyte senescence. Proc Natl Acad Sci USA 2012; 109:1133-8; PMID:22228303; http://dx.doi.org/10.1073/pnas.1112257109.
19. Candi E, Rufini A, Terrinoni A, Dinsdale D, Ranalli M, Paradisi A, et al. Differential roles of p63 isoforms in epidermal development: selective genetic complementation in p63 null mice. Cell Death Differ 2006; 13:1037-47; PMID:16601749; http://dx.doi.org/10.1038/sj.cdd.4401926.
20. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398:714-8; PMID:10227294; http://dx.doi.org/10.1038/ 19539.
21. Candi E, Terrinoni A, Rufini A, Chikh A, Lena AM, Suzuki Y, et al. p63 is upstream of IKK alpha in epidermal development. J Cell Sci 2006; 119:4617-22; PMID:17093266; http://dx.doi.org/10.1242/jcs.03265.
22. Carroll DK, Carroll JS, Leong CO, Cheng F, Brown M, Mills AA, et al. p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol 2006; 8:551-61; PMID:16715076; http://dx.doi.org/10.1038/ncb1420.
23. Melino G. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ 2011; 18:1487-99; PMID:21760596; http://dx.doi.org/10.1038/cdd.2011.81.
24. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139:1327-41; PMID:20064378; http://dx.doi.org/10.1016/j.cell.2009.11.026.
25. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009; 137:87-98; PMID:19345189; http://dx.doi.org/10.1016/j.cell.2009.01.039.
26. Park BJ, Lee SJ, Kim JI, Lee SJ, Lee CH, Chang SG, et al. Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res 2000; 60:3370-4; PMID:10910040.
27. Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL, et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 2010; 467:986-90; PMID:20962848; http://dx.doi.org/10.1038/nature09459.
28. Su X, Gi YJ, Chakravarti D, Chan IL, Zhang A, Xia X, et al. TAp63 is a master transcriptional regulator of lipid and glucose metabolism. Cell Metab 2012; 16:511-25; PMID:23040072; http://dx.doi.org/10.1016/j.cmet.2012.09.006.
29. Warburg O. On the origin of cancer cells. Science 1956; 123:309-14; PMID:13298683; http://dx.doi.org/10.1126/science.123.3191.309.
30. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008; 18:54-61; PMID:18387799; http://dx.doi.org/10.1016/j.gde.2008.02.003.
31. DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010; 29:313-24; PMID:19881548; http://dx.doi.org/10.1038/onc.2009.358.
32. Peschiaroli A, Giacobbe A, Formosa A, Markert EK, Bongiorno-Borbone L, Levine AJ, et al. miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene 2013; 32:797-802; PMID:22469988; http://dx.doi.org/10.1038/onc.2012. 100.
33. Markert EK, Levine AJ, Vazquez A. Proliferation and tissue remodeling in cancer: the hallmarks revisited. Cell Death Dis 2012; 3:e397; PMID:23034332; http://dx.doi.org/10.1038/cddis.2012.140.
34. Lyssiotis CA, Vander-Heiden MG, Munoz-Pinedo C, Emerling BM. Emerging concepts: linking hypoxic signaling and cancer metabolism. Cell Death Dis 2012; 3:e303; PMID:22552280; http://dx.doi.org/10.1038/cddis.2012.41.
35. Qie S, Liang D, Yin C, Gu W, Meng M, Wang C, et al. Glutamine depletion and glucose depletion trigger growth inhibition via distinctive gene expression reprogramming. Cell Cycle 2012; 11:3679-90; PMID:22935705; http://dx.doi.org/10. 4161/cc.21944.
36. Gomes LC, Di Benedetto G, Scorrano L. Essential amino acids and glutamine regulate induction of mitochondrial elongation during autophagy. Cell Cycle 2011; 10:2635-9; PMID:21811092; http://dx.doi.org/10.4161/cc.10.16.17002.
37. Martin-Rufian M, Tosina M, Campos-Sandoval JA, Manzanares E, Lobo C, Segura JA, et al. Mammalian glutaminase Gls2 gene encodes two functional alternative transcripts by a surrogate promoter usage mechanism. PLoS One 2012; 7:e38380; PMID:22679499; http://dx.doi.org/10.1371/journal.pone.0038380.
38. Aledo JC, Gomez-Fabre PM, Olalla L, Marquez J. Identification of two human glutaminase loci and tissue-specific expression of the two related genes. Mamm Genome 2000; 11:1107-10; PMID:11130979; http://dx.doi.org/10.1007/ s003350010190.
39. Campos-Sandoval JA, Lopez de la Oliva AR, Lobo C, Segura JA, Mates JM, Alonso FJ, et al. Expression of functional human glutaminase in baculovirus system: affinity purification, kinetic and molecular characterization. Int J Biochem Cell Biol 2007; 39:765-73; PMID:17267261; http://dx.doi.org/10.1016/j. biocel. 2006.12.002.
40. Perez-Gomez C, Campos-Sandoval JA, Alonso FJ, Segura JA, Manzanares E, Ruiz-Sanchez P, et al. Co-expression of glutaminase K and L isoenzymes in human tumour cells. Biochem J 2005; 386:535-42; PMID:15496140; http://dx.doi.org/10. 1042/BJ20040996.
41. Turner A, McGivan JD. Glutaminase isoform expression in cell lines derived from human colorectal adenomas and carcinomas. Biochem J 2003; 370:403-8; PMID:12408749; http://dx.doi.org/10.1042/BJ20021360.
42. Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci USA 2010; 107:7455-60; PMID:20378837; http://dx.doi.org/10.1073/pnas. 1001006107.
43. Vousden KH, Ryan KM. p53 and metabolism. Nat Rev Cancer 2009; 9:691-700; PMID:19759539; http://dx.doi.org/10.1038/nrc2715.
44. Gressner O, Schilling T, Lorenz K, Schulze Schleithoff E, Koch A, Schulze-Bergkamen H, et al. TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J 2005; 24:2458-71; PMID:15944736; http://dx.doi.org/10.1038/sj.emboj.7600708.
45. Browne G, Cipollone R, Lena AM, Serra V, Zhou H, van Bokhoven H, et al. Differential altered stability and transcriptional activity of ΔNp63 mutants in distinct ectodermal dysplasias. J Cell Sci 2011; 124:2200-7; PMID:21652629; http://dx.doi.org/10.1242/jcs.079327.
46. Masse I, Barbollat-Boutrand L, Molina M, Berthier-Vergnes O, Joly-Tonetti N, Martin MT, et al. Functional interplay between p63 and p53 controls RUNX1 function in the transition from proliferation to differentiation in human keratinocytes. Cell Death Dis 2012; 3:e318; PMID:22673192; http://dx.doi.org/10. 1038/cddis.2012.62.
47. Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Vousden KH, et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci USA 2012; 109:15312-7; PMID:22949650; http://dx.doi.org/10.1073/pnas.1110977109.
48. Sayan BS, Yang AL, Conforti F, Bernardini S, Tucci P, Vasa-Nicotera M, et al. Induction of TAp63 by histone deacetylase inhibitors. Biochem Biophys Res Commun 2010; 391:1748-51; PMID:20043870; http://dx.doi.org/10.1016/j.bbrc.2009. 12.147.
49. Newbold A, Vervoort SJ, Martin BP, Bots M, Johnstone RW. Induction of autophagy does not alter the anti-tumor effects of HDAC inhibitors. Cell Death Dis 2012; 3:e387; PMID:22951984; http://dx.doi.org/10.1038/cddis.2012.128.
50. Mates JM, Segura JA, Martin-Rufian M, Campos-Sandoval JA, Alonso FJ, Marquez J. Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress against Cancer. Curr Mol Med 2012; In press; PMID:22934847.
51. Hsiao CH, Li W, Lou TF, Baliga BS, Pace BS. Fetal hemoglobin induction by histone deacetylase inhibitors involves generation of reactive oxygen species. Exp Hematol 2006; 34:264-73; PMID:16543060; http://dx.doi.org/10.1016/j.exphem. 2005.12.009.
52. Ben-Sahra I, Dirat B, Laurent K, Puissant A, Auberger P, Budanov A, et al. Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death. Cell Death Differ 2013; 20:611-9; PMID:23238567; http://dx.doi.org/10.1038/cdd.2012.157.
53. Nayak G, Cooper GM. p53 is a major component of the transcriptional and apoptotic program regulated by PI 3-kinase/Akt/GSK3 signaling. Cell Death Dis 2012; 3:e400; PMID:23059819; http://dx.doi.org/10.1038/cddis.2012.138.
54. Tucci P. Caloric restriction: is mammalian life extension linked to p53? Aging (Albany NY) 2012; 4:525-34; PMID:22983298.
55. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 2004; 64:2627-33; PMID:15059920; http://dx.doi.org/10.1158/0008-5472.CAN-03- 0846.
56. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, et al. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005; 65:177-85; PMID:15665293.
57. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126:107-20; PMID:16839880; http://dx.doi.org/10.1016/j.cell.2006.05.036.
58. Mathupala SP, Heese C, Pedersen PL. Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem 1997; 272:22776-80; PMID:9278438; http://dx.doi.org/10.1074/jbc.272.36.22776.
59. Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 2004; 304:596-600; PMID:15105503; http://dx.doi.org/10.1126/science. 1095569.
60. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nat Med 2005; 11:1306-13; PMID:16286925; http://dx.doi.org/10.1038/nm1320.
61. Yoon KA, Nakamura Y, Arakawa H. Identification of ALDH4 as a p53-inducible gene and its protective role in cellular stresses. J Hum Genet 2004; 49:134-40; PMID:14986171; http://dx.doi.org/10.1007/s10038-003-0122-3.
62. Rufini A, Niklison-Chirou MV, Inoue S, Tomasini R, Harris IS, Marino A, et al. TAp73 depletion accelerates aging through metabolic dysregulation. Genes Dev 2012; 26:2009-14; PMID:22987635; http://dx.doi.org/10.1101/gad.197640.112.
63. Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K, et al. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell 2002; 10:995-1005; PMID:12453409; http://dx.doi.org/10.1016/S1097-2765(02)00706-2.
64. Yan W, Chen X. GPX2, a direct target of p63, inhibits oxidative stress-induced apoptosis in a p53-dependent manner. J Biol Chem 2006; 281:7856-62; PMID:16446369; http://dx.doi.org/10.1074/jbc.M512655200.
65. Szeliga M, Obara-Michlewska M, Matyja E, Łazarczyk M, Lobo C, Hilgier W, et al. Transfection with liver-type glutaminase cDNA alters gene expression and reduces survival, migration and proliferation of T98G glioma cells. Glia 2009; 57:1014-23; PMID:19062176; http://dx.doi.org/10.1002/glia. 20825.
66. Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci USA 2010; 107:7461-6; PMID:20351271; http://dx.doi.org/10.1073/pnas.1002459107.
67. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 2008; 105:18782-7; PMID:19033189; http://dx.doi.org/10.1073/pnas.0810199105.
68. Hampton RY. ER stress response: getting the UPR hand on misfolded proteins. Curr Biol 2000; 10:R518-21; PMID:10898996; http://dx.doi.org/10.1016/ S0960-9822(00)00583-2.
69. Finkel T. Redox-dependent signal transduction. FEBS Lett 2000; 476:52-4; PMID:10878249; http://dx.doi.org/10.1016/S0014-5793(00)01669-0.
70. Meng TC, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 2002; 9:387-99; PMID:11864611; http://dx.doi.org/10.1016/S1097-2765(02)00445-8.
71. Peschiaroli A, Skaar JR, Pagano M, Melino G. The ubiquitin-specific protease USP47 is a novel beta-TRCP interactor regulating cell survival. Oncogene 2010; 29:1384-93; PMID:19966869; http://dx.doi.org/10.1038/onc.2009. 430.
72. Peschiaroli A, Figliola R, Coltella L, Strom A, Valentini A, D'Agnano I, et al. MyoD induces apoptosis in the absence of RB function through a p21(WAF1)-dependent re-localization of cyclin/cdk complexes to the nucleus. Oncogene 2002; 21:8114-27; PMID:12444547; http://dx.doi.org/10.1038/sj.onc. 1206010.
73. Sengupta S, den Boon JA, Chen IH, Newton MA, Dahl DB, Chen M, et al. Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma. Cancer Res 2006; 66:7999-8006; PMID:16912175; http://dx.doi.org/10.1158/0008-5472.CAN-05-4399.
74. Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One 2010; 5:e10312; PMID:20421987; http://dx.doi.org/10.1371/journal.pone.0010312.
75. Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 2006; 24:1679-88; PMID:16549822; http://dx.doi.org/10. 1200/JCO.2005.03.8224.